Pharmacological and Computational Approach to Eslicarbazepine: A Short Review
Nadeem Siddiqui¹*, M. Shamsher Alam¹, Sharique Ahmed², Ruhi Ali¹, M. Faiz Arshad¹ and Waquar Ahsan¹¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hamdard University, Hamdard Nagar, New Delhi - 110 062 India.
²Department Biochemistry, Faculty of Medicine, 7th October University, Misurata India.
Corresponding Author E-mail:nadeems_03@rediffmail.com
Abstract: Sepracor Inc. (Nasdaq: SEPR) announced the presentation of Phase III combined clinical results for eslicarbazepine acetate (SEP-0002093 / BIA 2-093) in the treatment of epilepsy at the Ninth Eilat Conference on New Anti-Epileptic Drugs in Spain. The study demonstrates that eslicarbazepine is well tolerated and effective when used as adjunct therapy for adult patients with partial epilepsy with distinctively lesser side effects. The pharmacological and computational properties of eslicarbazepine have been studied and discussed.
Keywords: Eslicarbazepine; Pharmacokinetics; Antiepileptic; Computational Back to TOC